Phase I Dose-Escalation Extension Study to Determine the Safety and Tolerability of Intratumoural Injection(s) of EBC-46

Trial Profile

Phase I Dose-Escalation Extension Study to Determine the Safety and Tolerability of Intratumoural Injection(s) of EBC-46

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Tigilanol tiglate (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Skin cancer
  • Focus Adverse reactions
  • Sponsors QBiotics
  • Most Recent Events

    • 19 Jul 2017 Status changed from recruiting to completed.
    • 08 Sep 2016 Planned number of patients changed from 30 to 15.
    • 19 Mar 2015 Planned initiation date changed from 22 Dec 2014 to 13 Mar 2015, as reported by Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top